Subtype
Pancreatobiliary Carcinoma
CI-CAN-00001365Explore in graph →
699 active trials8 approved drugs60 evidence items
- NCIt
- C166418
Loading cancer entity…
Subtype
CI-CAN-00001365Explore in graph →
Clinical trials
2,131 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (303)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06608927 | Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma(PRISM-1) | active not recruiting | Phase 3 | 610 | Arcus Biosciences, Inc.INDUSTRY | 13 | Sep 29, 2026 | clinicaltrials |
| NCT07621718 | Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )(RASolute 305) | recruiting | Phase 3 | 670 | Revolution Medicines, Inc. |
| 2 |
| Sep 28, 2026 |
| clinicaltrials |
| NCT06989437 | A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue | recruiting | Phase 2 / Phase 3 | 982 | PfizerINDUSTRY | 21 | Sep 25, 2026 | clinicaltrials |
| NCT07562152 | Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma(MAPKeeper 301) | recruiting | Phase 3 | 510 | Immuneering CorporationINDUSTRY | 4 | Sep 25, 2026 | clinicaltrials |
| NCT07252232 | Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)(RASolute 304) | recruiting | Phase 3 | 500 | Revolution Medicines, Inc.INDUSTRY | 9 | Sep 23, 2026 | clinicaltrials |
| NCT07409272 | A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer | recruiting | Phase 3 | 614 | Astellas Pharma Global Development, Inc.INDUSTRY | 6 | Sep 22, 2026 | clinicaltrials |
| NCT05482516 | Evaluating Novel Therapies in ctDNA Positive GI Cancers(MRD-GI) | recruiting | Phase 3 | 20 | Georgetown UniversityOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT07491445 | Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma(RASolute 303) | recruiting | Phase 3 | 900 | Revolution Medicines, Inc.INDUSTRY | 10 | Sep 14, 2026 | clinicaltrials |
| NCT07081360 | Neoadjuvant vs Upfront Surgery for Resectable Pancreatic Cancer and Periampullary Cancer | recruiting | Phase 3 | 262 | Minia UniversityOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT06037980 | CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative Chemotherapy Versus Immediate Resection in patIents With resecTable BiliarY Tract Cancers (BTC) at High Risk for Recurrence(PURITY) | recruiting | Phase 2 / Phase 3 | 300 | Gruppo Oncologico del Nord-OvestOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT07805954 | Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mutated Pancreatic Adenocarcinoma(RASolute 309) | recruiting | Phase 3 | 400 | Revolution Medicines, Inc.INDUSTRY | 1 | Sep 8, 2026 | clinicaltrials |
| NCT04340141 | Testing the Use of the Usual Chemotherapy Before and After Surgery for Removable Pancreatic Cancer | active not recruiting | Phase 3 | 358 | Alliance for Clinical Trials in OncologyOTHER | 2 | Sep 4, 2026 | clinicaltrials |
| NCT07803783 | A Study to Compare the Efficacy and Safety of YL201 With Standard Chemotherapy in Patients With Metastatic Pancreatic Cancer After Failure of Gemcitabine-Based Systemic Chemotherapy | not yet recruiting | Phase 3 | 320 | MediLink Therapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Sep 4, 2026 | clinicaltrials |
| NCT05506943 | A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002) | active not recruiting | Phase 2 / Phase 3 | 168 | Compass TherapeuticsINDUSTRY | 1 | Sep 2, 2026 | clinicaltrials |
| NCT06923475 | Neoadjuvant Gemcitabine and Cisplatin in Combination With Perioperative Pembrolizumab Versus Upfront Surgery for Patients With Primary Resectable and Borderline Resectable Perihilar and Distal Cholangiocarcinoma(NEODISCO) | recruiting | Phase 2 / Phase 3 | 150 | Amsterdam UMC, location VUmcOTHER | 1 | Aug 25, 2026 | clinicaltrials |
| NCT06958328 | Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer(LAP100) | recruiting | Phase 3 | 356 | NRG OncologyOTHER | 2 | Aug 25, 2026 | clinicaltrials |
| NCT07765433 | Testing the Addition of Ivonescimab Combined With Standard Chemotherapy Compared to the Usual Chemotherapy and Immunotherapy Treatment for Patients With Advanced Biliary Tract Cancer | not yet recruiting | Phase 2 / Phase 3 | 336 | ECOG-ACRIN Cancer Research GroupNETWORK | 0 | Aug 14, 2026 | clinicaltrials |
| NCT05876754 | An Early Access Study of Ivosidenib in Patients With a Pretreated Locally Advanced or Metastatic Cholangiocarcinoma(ProvIDHe) | active not recruiting | Phase 3 | 299 | Servier Affaires MédicalesINDUSTRY | 16 | Jul 31, 2026 | clinicaltrials |
| NCT06506955 | Futibatinib in Patients Previously Enrolled in an Antecedent Futibatinib as Monotherapy or Combination Therapy. | active not recruiting | Phase 2 / Phase 3 | 15 | Taiho Oncology, Inc.INDUSTRY | 5 | Jul 28, 2026 | clinicaltrials |
| NCT06593431 | Extending Outcomes for Pancreas Cancer Patients With Nominal Oligometastatic Disease (EXPAND): A Randomized Phase III Trial | recruiting | Phase 3 | 80 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 27, 2026 | clinicaltrials |
| NCT07711067 | A Study Comparing Whole-Body Heat Treatment Plus Systemic Therapy to Systemic Therapy Alone, for Advanced Pancreatic Cancer(MATTERS-2) | not yet recruiting | Phase 2 / Phase 3 | 95 | ElmediXINDUSTRY | 2 | Jul 17, 2026 | clinicaltrials |
| NCT07691515 | Intraarterial Therapies Plus Tislelizumab Plus Lenvatinib Versus Tislelizumab Plus Gemcitabine-Cisplatin in Unresectable Intrahepatic Cholangiocarcinoma(RAINBOW) | not yet recruiting | Phase 3 | 140 | Zhejiang Cancer HospitalOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT05948475 | Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma(FIRST-308) | active not recruiting | Phase 3 | 200 | TransThera Sciences (Nanjing), Inc.INDUSTRY | 13 | Jul 6, 2026 | clinicaltrials |
| NCT07656376 | Clinical Trial of DN022150 Combined With AG Chemotherapy as First-line Treatment for Locally Advanced or Metastatic Pancreatic Cancer With KRAS G12D Mutation | not yet recruiting | Phase 2 / Phase 3 | 465 | Jiangxi Kvvit Pharmaceutical Co., Ltd.INDUSTRY | 0 | Jun 18, 2026 | clinicaltrials |
| NCT07219238 | Study to Evaluate the Diagnostic Performance of GEH300079 (68Ga) Injection PET/CT for Detection of PC in Patients With Colorectal, Gastric, Ovarian, or Pancreatic Cancers (PERISCOPE) | recruiting | Phase 2 / Phase 3 | 175 | GE HealthcareINDUSTRY | 2 | Jun 17, 2026 | clinicaltrials |
| NCT07076121 | A Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30) | active not recruiting | Phase 2 / Phase 3 | 470 | Bristol-Myers SquibbINDUSTRY | 36 | Jun 3, 2026 | clinicaltrials |
| NCT06625320 | Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)(RASolute 302) | active not recruiting | Phase 3 | 500 | Revolution Medicines, Inc.INDUSTRY | 7 | Jun 2, 2026 | clinicaltrials |
| NCT06851663 | Trop2-targeted immunoPET Imaging of Solid Tumors | recruiting | Phase 2 / Phase 3 | 400 | RenJi HospitalOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT06998940 | Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations | recruiting | Phase 3 | 94 | SWOG Cancer Research NetworkNETWORK | 1 | May 22, 2026 | clinicaltrials |
| NCT07598318 | Study of Becotatug Vedotin Added to Standard Treatment for Advanced Bile Duct Cancer With EGFR Mutations | not yet recruiting | Phase 2 / Phase 3 | 164 | Sir Run Run Shaw HospitalOTHER | 0 | May 20, 2026 | clinicaltrials |
| NCT04927780 | Perioperative or Adjuvant mFOLFIRINOX for Resectable Pancreatic Cancer(PREOPANC-3) | active not recruiting | Phase 3 | 378 | Erasmus Medical CenterOTHER | 2 | May 15, 2026 | clinicaltrials |
| NCT06807437 | Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic Fistula | recruiting | Phase 3 | 274 | SWOG Cancer Research NetworkNETWORK | 1 | Mar 31, 2026 | clinicaltrials |
| NCT06861088 | The Effect of Kinisoquin™ on Thromboembolic Events in Patients With Metastatic or Locally Advanced Pancreatic Cancer(CATIQ P3) | recruiting | Phase 3 | 480 | Quercis Pharma AGINDUSTRY | 1 | Feb 2, 2026 | clinicaltrials |
| NCT07328919 | Efficacy and Safety of TT-00420 (Tinengotinib) Tablets Versus Chemotherapy in Patients With Advanced Intrahepatic Cholangiocarcinoma Harboring FGFR2 Fusions/Rearrangements or Mutations | not yet recruiting | Phase 3 | 138 | TransThera Sciences (Nanjing), Inc.INDUSTRY | 1 | Jan 9, 2026 | clinicaltrials |
| NCT06115499 | The PLATINUM Trial: Optimizing Chemotherapy for the Second-Line Treatment of Metastatic BRCA1/2 or PALB2-Associated Metastatic Pancreatic Cancer | active not recruiting | Phase 2 / Phase 3 | 10 | Alliance for Clinical Trials in OncologyOTHER | 1 | Jan 7, 2026 | clinicaltrials |
| NCT04353375 | HMPL-453 Tartrate in Advanced Intrahepatic Cholangiocarcinoma | recruiting | Phase 2 / Phase 3 | 235 | HutchmedINDUSTRY | 1 | Dec 31, 2025 | clinicaltrials |
| NCT02000089 | The Cancer of the Pancreas Screening-5 CAPS5)Study(CAPS5) | recruiting | Phase 3 | 9,000 | Johns Hopkins UniversityOTHER | 1 | Oct 9, 2025 | clinicaltrials |
| NCT07155525 | Tissue Adhesive Glue Modified Cyanoacrylate (Glubran® 2) in Soft Pancreas(NBCA-MS) | recruiting | Phase 3 | 194 | Minia UniversityOTHER | 1 | Sep 18, 2025 | clinicaltrials |
| NCT04669496 | Phase II-III Clinical Trial of PD1 Antibody (Toripalimab), Lenvatinib and GEMOX Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors | active not recruiting | Phase 2 / Phase 3 | 178 | Shanghai Zhongshan HospitalOTHER | 1 | Sep 4, 2025 | clinicaltrials |
| NCT06095141 | Cisplatin to Patients With Pancreatic Cancer and Homologous Recombination Deficiency(PTCA199-6) | recruiting | Phase 2 / Phase 3 | 30 | Fudan UniversityOTHER | 1 | Aug 7, 2025 | clinicaltrials |
| NCT06250972 | Radiotherapy to Patients With CA19-9-elevated Advanced Pancreatic Cancer(PTCA199-11) | recruiting | Phase 3 | 210 | Fudan UniversityOTHER | 1 | Aug 7, 2025 | clinicaltrials |
| NCT07062263 | Trastuzumab Plus Chemotherapy vs Chemotherapy Alone in First-line HER2 Positive Advanced Biliary Tract Cancer Patients(TAB-2) | recruiting | Phase 3 | 220 | Tata Memorial CentreOTHER | 1 | Jul 14, 2025 | clinicaltrials |
| NCT06332274 | tislelizUMaB in canceR Patients With molEcuLar residuaL Disease(UMBRELLA) | recruiting | Phase 3 | 717 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | May 13, 2025 | clinicaltrials |
| NCT05342194 | Toripalimab Plus Lenvatinib and Gemcitabine-based Chemotherapy in 1L Treatment of Advanced ICC: a Phase III Study | recruiting | Phase 3 | 480 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 1 | Apr 23, 2025 | clinicaltrials |
| NCT06355427 | The Effect of [18F] F-FAPI PET-CT on Management in Patients With Proximal Cholangiocarcinoma(FAPIChol) | recruiting | Phase 2 / Phase 3 | 81 | Mara Veenstra, MDOTHER | 1 | Apr 11, 2025 | clinicaltrials |
| NCT02170090 | Adjuvant Chemotherapy With Gemcitabine and Cisplatin Compared to Standard of Care After Curative Intent Resection of Biliary Tract Cancer(ACTICCA-1) | active not recruiting | Phase 3 | 789 | Universitätsklinikum Hamburg-EppendorfOTHER | 8 | Mar 30, 2025 | clinicaltrials |
| NCT06782412 | Multicenter Validation Trial of [18F]AlF-FAPI-74 for PET Imaging of Cancer-associated Fibroblasts Through Fibroblast Activation Protein Inhibitors (FAPI) in Different Tumor Types(FAPIDO) | recruiting | Phase 2 / Phase 3 | 109 | KU LeuvenOTHER | 1 | Feb 7, 2025 | clinicaltrials |
| NCT01954992 | Glufosfamide Versus 5-FU in Second Line Metastatic Pancreatic Cancer | recruiting | Phase 3 | 480 | Eleison Pharmaceuticals LLC.INDUSTRY | 1 | Dec 31, 2024 | clinicaltrials |
| NCT06714604 | Standard or Prolonged Neoadjuvant Chemotherapy Before Surgery for BR/LAPC(ADVANTAGE) | recruiting | Phase 3 | 432 | Sahlgrenska University HospitalOTHER | 1 | Dec 3, 2024 | clinicaltrials |
| NCT05254171 | Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer(ASPIRE) | recruiting | Phase 2 / Phase 3 | 600 | Panbela Therapeutics, Inc.INDUSTRY | 10 | Nov 6, 2024 | clinicaltrials |
Data updated 10 hours agoSource updated Sep 29, 2026source: clinicaltrials